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Metronomic chemotherapy in non-small- 
-cell lung cancer — current status
ABSTRACT
Chemotherapy remains a standard treatment of advanced non-small-cell lung cancer. Metronomic chemotherapy 
– frequent administration of low-dose cytotoxic agents – may be a new option with minimal toxicity. This method 
may have complex mechanisms of action — the antiangiogenic effects and modulation of the immune system 
are crucial. Vinorelbine could be an option for non-small-cell lung cancer patients because of it has favourable 
safety profile and the oral form of the drug is easy to administer. There are some studies documenting the clinical 
activity of oral vinorelbine in advanced non-small-cell lung cancer patients. However, further prospective studies 
are necessary to assess the place of metronomic chemotherapy in clinical practice.
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Introduction
Palliative chemotherapy is a standard of care in 
patients with advanced non-small-cell lung cancer 
(NSCLC) without activating mutations in the EGFR 
gene. Platinum-based doublet chemotherapy could be 
considered in patients with satisfactory performance 
status without significant comorbidities. In elderly 
patients or in case of worse performance status, ei-
ther monotherapy (most frequently vinorelbine or 
gemcitabine) or best supportive care (BSC) should be 
considered [1]. According to the standard schedules of 
administration of cytotoxic drugs, they should be ad-
ministered in maximum tolerated doses in 21-day cycles 
[1]. The duration of time intervals between subsequent 
chemotherapy cycles results mainly from the necessity to 
recover from myelosuppression. At the same time there 
are some changes observed in stroma and blood vessels 
of cancer, which adversely influence the final treatment 
efficacy and consequently could lead to resistance to 
chemotherapy [2]. Regeneration of endothelium of 
cancer vasculature is the main mechanism causing these 
effect. It was observed that more frequent administra-
tion of some cytotoxic drugs (e.g. cyclophosphamide, 
methotrexate, gemcitabine, and vinorelbine) in lower 
doses could have an antiangiogenic affect [3, 4]. This pat-
tern of cytotoxic drugs administration was named met-
ronomic chemotherapy, and the last two years brought 
new evidence on the mechanism of action, anticancer 
effectiveness, and safety of this method.
The majority of published data regarding metro-
nomic chemotherapy is based on experience in patients 
with breast cancer, NSCLC and prostate cancer [5]. The 
use of vinorelbine in patients with advanced NSCLC is 
of the highest importance.
This review presents theoretical rationale underlying 
metronomic chemotherapy and available data on met-
ronomic chemotherapy with the use of oral vinorelbine 
in patients with advanced NSCLC.
Mechanism of action of metronomic 
chemotherapy
The efficacy of metronomic chemotherapy, to a very 
limited extent, depends on direct cytotoxic activity, 
and a major role is played by antiangiogenic and im-
munomodulatory effects [6].
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Antiangiogenic effect
The antiangiogenic effect is related to impaired 
function of endothelial cells of cancer blood vessels, 
leading to inhibition of their proliferation and migra-
tion as well as to induction of apoptosis [3, 4]. Increased 
thrombospondin-1 (TSP-1) level, a protein potently 
inhibiting angiogenesis, is also responsible. Thrombos-
pondin-1 inhibits angiogenesis directly in connection 
with induction of apoptosis and inhibition of migration 
of endothelial cells, and indirectly though growth factor 
[7]. Lower mobilisation of progenitor endothelial cells 
from bone marrow is also observed [5].
Immunomodulatory effect
Recent years have brought important progress in 
immunotherapy of cancers, and the efficacy of immuno-
competent drugs (so called checkpoint inhibitors — e.g. 
ipilimumab, nivolumab, pembrolizumab) in some malig-
nancies (e.g. NSCLC, melanoma) has already been estab-
lished. Although the anticancer activity of cytotoxic drugs 
is based on their direct influence on cancer cells, they are 
also able to modulate immune system functions. Metro-
nomic chemotherapy could enhance the immunomodula-
tory effect with minimal immunosuppression [2]. Among 
the mechanisms responsible for such effects are induction 
of immune-dependent apoptosis, increased antigen pres-
entation by dendritic cells, and intensification of cancer 
cell immunogenicity. Additionally, decreasing regulatory 
T-cell numbers are observed. Long-term stimulation of 
the effects that are beneficial for anticancer treatment 
could allow prolongation of the time of cancer control. 
A synergistic effect of metronomic chemotherapy and 
immunocompetent drugs was also suggested [2].
Vinorelbine
Vinorelbine is a member of the vinca alkaloids family 
of cytotoxic drugs. It binds to mitotic microtubules and 
inhibits cell cycle in the G2-M phase, leading to death of 
the cell within the interphase or any subsequent mitotic 
stage [8]. There are two available forms of the drug: 
intravenous and oral (estimated bioavailability of oral 
vinorelbine is appeoximately 40%). The mean half-life 
of the drug is about 40 hours; however, the half-life of 
the active metabolite (4-O-deacetylvinorelbine) is up 
to 168 hours [9]. Vinorelbine is metabolised in the liver 
through CYP3A4 cytochrome and is excreted with bile. 
It is recommended that entire vinorelbine capsules are 
swallowed with a small amount of water [10].
Standard chemotherapy
Vinorelbine was initially used intravenously only in 
NSCLC patients, and its effectiveness was confirmed 
in palliative chemotherapy (either monotherapy or 
platinum-based doublets) as well as in treatment 
combined with radical therapy modalities (chemo-ra-
diotherapy, postoperative adjuvant chemotherapy with 
platinum-based doublets). Development of the oral form 
of vinorelbine led to establishment of an optimal dosing 
schedule and then the conduction of clinical trials assess-
ing the efficacy and safety of the drug. It was determined 
that an intravenous dose of 30 mg/m2 is equal to an oral 
dose of 80 mg, and a dose of 25 mg/m2 is equal to an 
oral dose of 60 mg. It was also stated that the optimal 
schedule of oral vinorelbine dosing is to administer 
a dose of 60 mg/m2 in the first cycle (days 1, 8, and 15) 
and dose escalation is possible up to 80 mg/m2 in patients 
with acceptable toleration of the treatment (mainly 
haematological) [11, 12]. 
A total of 115 patients with advanced NSCLC were 
enrolled to prospective phase II clinical trials with the 
primary endpoint to assess objective response rate (ORR). 
Progression-free survival (PFS), overall survival (OS), and 
safety profile of both forms of vinorelbine were also evalu-
ated [12]. It was shown that the efficacy of oral and intra-
venous vinorelbine form was comparable in reference to 
ORR (14% vs. 12%). Median PFS was 3.2 and 2.1 months, 
respectively, and median of survival time was 9.3 months 
and 7.9 months, respectively. Small differences in toxic-
ity profiles of both forms of vinorelbine were observed. 
Figure 1. Metronomic chemotherapy — mechanisms of action (based on [2])
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The most common adverse reactions among patients treat-
ed with oral vinorelbine were nausea and vomiting (83% 
and 65%, respectively), anaemia (86%) and neutropaenia 
(63%). In patients receiving intravenous vinorelbine the 
most common side effects included neutropaenia (89%), 
anaemia (84%), weight loss (49%), and nausea (46%). 
Table 1 presents the data regarding adverse effects emerg-
ing during treatment with vinorelbine in presented trial [12].
Efficacy of oral vinorelbine monotherapy was evalu-
ated in several other prospective phase II studies. In the 
majority of them the drug was used in a stable dose of 
60 mg/m2 weekly without dose escalation. The clinical 
trials that included elderly patients (≥ 70 years) and pa-
tients with worse performance status (PS) [2 according 
to the Eastern Cooperative Oncology Group (ECOG) 
scale] should be especially highlighted, and clinical ben-
efit was also observed in these groups of patients. The 
detailed presentation of all studies exceeds the publi-
cation frame. Table 2 summarises the most important 
results of the studies published to date in which oral 
vinorelbine was used in patients with advanced NSCLC. 
Metronomic chemotherapy — monotherapy
Metronomic chemotherapy is based on using cy-
totoxic drugs with increased frequency. The oral way 
of administration seems to be the most convenient for 
the patients. The efficacy and safety of oral vinorelbine 
used within metronomic chemotherapy were assessed 
in radically treated patients with NSCLC as well as in 
patients with only palliative chemotherapy. A very im-
portant result was establishing the dosing schedule and 
maximum tolerated does (MTD). 
In a phase I study conducted in 73 patients with ad-
vanced recurring solid tumours (breast cancer, NSCLC, 
and prostate cancer) vinorelbine was used in three 
different doses (30, 40, or 50 mg) administered three 
times a week [20]. In this study the parameters of treat-
ment efficacy (time to treatment failure was compared 
between three subgroups after four and six months), 
adverse effects, as well as the levels of potential angio-
genesis markers [fibroblast growth factor type 2 (FGF2), 
vascular endothelial growth factor (VEGFA), interleu-
kin 8 — IL-8, and TSP-1] were analysed. Based on the 
results, the authors concluded that oral vinorelbine in 
the dose of 50 mg given three times a week is optimal 
treatment. They also determined a predictive level of 
FGF2 and IL-8. The most common treatment-related 
adverse effects were anaemia and neutropaenia [20].
In other publications assessing the safety of oral met-
ronomic vinorelbine in patients with advances cancers 
the dose of 50 mg was also recognised as optimal [9, 21].
Table 1. Side effects of vinorelbine used in standard dosage (based on [12])
Oral vinorelbine Intravenous vinorelbine
Total (%) Grade 3–4 (%) Total (%) Grade 3–4 (%)
Anaemia 86 5 84 –
Neutropaenia 63 46 89 62
Neutropaenic Fever – 3 – 8
Nausea 83 11 46 –
Diarrhoea 40 3 16 0
Loss of body weight 45 0 49 3
Table 2. The results of selected clinical trials assessing the efficacy of oral vinorelbine monotherapy (standard dosing)
Author Treatment  
line
Patients  
number
Drugs ORR (%) PFS (months) OS (months)
Jassem et al. [12] I 115 VRB p.o. vs. VRB i.v. 14 vs. 12 3.2 vs. 2.1 9.3 vs. 7.9
Chen et al. [13]* I 117 VRB vs. ERL 8.9 vs. 22.8 2.53 vs. 4.57 9.3 vs. 11.67  
(p = 0.6957)
Camerini et al. [14]* I 43 VRB 18.6 4.0 8.0
Gridelli et al. [15]* I 56 VRB 11.0 3.7 8.2
Kanard et al. [16]* I 58 VRB 3.4 3.5 7.5
Hirsch et al. [17] I 189 VRB p.o. vs. VRB i.v. 4 vs. 13 3.8 vs. 5.5 6.0 vs. 9.0
Kosmidis et al. [18]* I 74 VRB vs. PXL 6 vs. 13 2.1 vs. 2.6 3.1 vs. 5.1 (p = 0.95)
Rossi et al. [19] II 20 VRB 0 2.0 4.0
*Studies including elderly patients and/or patients in moderate performance status (ECOG = 2)
VRB — vinorelbine; ERL — erlotinib; PXL — paclitaxel; ORR — objective response rate; PFS — progression-free survival; OS — overall survival
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Table 3. The results of phase II clinical trials in patients with advanced NSCLC receiving monotherapy with oral metronomic 
vinorelbine
Author Patients  
number
Mean age PS = 2 (%) ORR% PFS OS
Camerini et al. [22] 43 80 62 19 5 9
Kontopodis et al. [23] 46 65 19 11 2.2 9.4
PS — performance status; ORR — objective response rate; PFS — progression-free survival; OS — overall survival
Table 4. Adverse effects during monotherapy with oral metronomic vinorelbine in patients with advanced NSCLC based 
on the results of published phase II studies
Total (%) Grade 3–4 (%)
Camerini et al. [22] Kontopodis et al. [23] Camerini et al. [22] Kontopodis et al. [23]
Anaemia 44 58.6 0.1 4.3
Neutropaenia 4 28 0.1 24
Fatigue 32 54.4 0.1 10.9
Diarrhoea 10 8.7 0.1 2.2
Nausea 8 13.0 0 2.2
Vomiting 5 15.2 0 4.3
Based on the results of presented trials a phase II 
clinical study was designed in patients with advanced 
NSCLC, who received in a first line systemic treat-
ment a recommended dose of oral vinorelbine [22]. 
The analysis included a group of 43 patients at the age 
of ≥ 70 years with cancer in stage IIIB or IV and in good 
or moderate PS (ECOG 0–2). Patients were treated 
until disease progression or unacceptable toxicity was 
documented. Objective response rate (ORR) and safety 
were assessed as well as quality of life (QoL) and in some 
of the patients VEGF and TSP1 level. In the analysed 
group ORR was 19%. Nearly 60% of patients had clini-
cal benefit during treatment (disease control lasting at 
least 12 weeks since treatment initiation). Median PFS 
was five months and median OS was nine months; 37% 
of the patients were still during follow-up after one year. 
The most common adverse effects during treatment was 
anaemia (44%), fatigue (32%), and diarrhoea (10%). 
Table 3 presents the detailed data. No negative influ-
ence on QoL was observed, defined by results obtained 
in the Functional Assessment Cancer Therapy — Lung 
(FACT-L) questionnaire. A higher level of VEGF 
before treatment initiation was a predictive factor of 
response to metronomic vinorelbine [22].
The authors of another publication analysed the ef-
ficacy and safety of oral metronomic vinorelbine used in 
second and further lines of palliative chemotherapy [23]. 
Response and survival rates as well as safety profile were 
assessed in a group of 46 patients. In general, ORR was 
noted in 11% of patients and another 20% of patients 
showed disease stabilisation. Median PFS and OS were 
2.2 and 9.4 months, respectively; 30% of the patients 
were still undergoing observation after one year. The 
most common adverse effects during treatment were 
anaemia (58%) and neutropenia (28%), which in 11% 
of cases were complicated by neutropaenic fever. The 
most common non-haematological toxicity was fatigue 
(54%). Table 4 presents the detailed data.
Metronomic chemotherapy — doublet protocols
Recently the results of clinical trials conducted in 
population of patients with advanced NSCLC were 
also published, in which oral metronomic vinorelbine 
was used in combination with other anticancer drugs 
[24, 25]. The first study analysed the efficacy of met-
ronomic vinorelbine combined with sorafenib [24]. 
The study design divided the total group of 46 patients 
into three cohorts, depending on vinorelbine dose (60, 
90, or 120 mg weekly, respectively). Additionally, the 
sorafenib dose was escalated depending on treatment 
tolerance. Initial sorafenib dose was 200 mg twice daily 
and maximum dose was 800 mg twice daily. Therapeu-
tic responses, survival parameters, safety profile, and 
predictive level of angiogenesis markers (among others 
TSP-1 and circulating endothelial cells) were assessed. 
Furthermore, changes in tumour vasculature were 
analysed using dynamic, contrast-enhanced magnetic 
resonance (DCE-MR). The rate of ORR in the whole 
analysed population was 9%, and 65% showed clinical 
benefit. Median PFS and OS were 4.4 and 8.2 months, 
respectively. Small sample size and different doses of 
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assessing drugs makes conclusions regarding optimal 
treatment and unequivocal safety profile very difficult. 
Multivariable analysis indicated independent predictive 
levels of biomarkers (number of circulating endothelial 
cells, DCE-MRI parameters) [24].
Another prospective phase II clinical trial assessed 
vinorelbine given in the dose of 60 mg three times in 
week combined with cisplatin in a standard dose of 
80 mg/m2 every 21 days [25]. The study included 41 patients 
with advanced NSCLC in good PS. Thirty-seven percent 
of patients obtained partial responses and another 28% 
of patients had a disease stabilisation. Median PFS was 
4.2 months, and median OS was 12 months. Fifty-two% 
of the patients were still undergoing observation after 
one year. The majority of patients experienced hae-
matological toxicities (anaemia — 85%, leukopaenia 
— 40%, neutropaenia — 54%). Three patients had 
a neutropaenic febrile during treatment as a complica-
tion [25].
There is another study currently ongoing, aiming to 
assess the efficacy of metronomic vinorelbine in com-
bination with bevacizumab (NCT00755170). In other 
trial the clinical value of metronomic vinorelbine will 
be analysed in patients with advanced NSCLC after 
platinum-based chemotherapy (NCT02176369) [26].
Summary
Recent years have brought new evidence regard-
ing metronomic chemotherapy. It is already known 
that the immunomodulatory effect plays an important 
role, together with antiangiogenic activity. The highest 
number of publications concerns metronomic use of 
cyclophosphamide and vinorelbine (agents that have 
already been used for many years in standard doses). 
Vinorelbine is a drug of potential clinical value in 
NSCLC patients. Already published data indicate a very 
good safety profile, particularly in NSCLC patients in 
good and moderate PS receiving vinorelbine in first-line 
treatment [22]. However, it should be underlined that 
to date there have been no results of a phase III clini-
cal study aimed at comparing the efficacy and safety 
of vinorelbine given in standard dosing schedules with 
metronomic vinorelbine in NSCLC patients. It is im-
portant to assess the subgroup of patients who could 
benefit from metronomic chemotherapy the most. Au-
thors publishing in this field suggest that metronomic 
chemotherapy should be considered in elderly patients 
with contraindications to platinum-based doublet 
chemotherapy. Metronomic chemotherapy could be 
also a therapeutic option for patients previously treated 
with palliative chemotherapy [23]. 
Metronomic chemotherapy is not a standard care in 
NSCLC patients. Prospective randomised clinical trials 
should be conducted, the results of which could allow 
the determination of actual clinical benefit. One of the 
important elements should be prospective analysis of 
QoL in patients treated with metronomic chemotherapy, 
which should in principle be used continuously up to dis-
ease progression. Identification of predictive factors in 
reference to antiangiogenic effectiveness of this therapy 
is another point of interest, together with analysis of the 
efficacy of metronomic chemotherapy combined with 
immunomodulatory and antiangiogenic drugs. 
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